Drilldown: Medicines
Medicines > classes 
:
Cathinone or
Empathogen or
[[:Category:Mast_cell_stabilizers|Mast cell stabilizer]]
:
Cathinone or
Empathogen or
[[:Category:Mast_cell_stabilizers|Mast cell stabilizer]] Use the filters below to narrow your results.
generic:
3-MMC (1) ·
4-FA (1) ·
5-APB (1) ·
5-MAPB (1) ·
6-APB (1) ·
6-APDB (1) ·
Azelastine (1) ·
Butylone (1) ·
Cathinone (1) ·
Ephylone (1) ·
Ethcathinone (1) ·
Ethylone (1) ·
Hexedrone (1) ·
Ketotifen (1) ·
MDA (1) ·
MDAI (1) ·
MDEA (1) ·
MDMA (1) ·
Mephedrone (1) ·
Methcathinone (1) ·
Methylone (1) ·
Mexedrone (1) ·
N-Ethylhexedrone (1) ·
N-Ethylpentedrone (1) ·
Olopatadine (1) ·
Pentedrone (1) ·
PMA (1) ·
PMMA (1)
brand:
classes: (Click arrow to add another value)
mechanism:
Cathinone analogue; monoamine reuptake inhibitor (2) ·
MAO inhibitor; monoamine releasing agent (1) ·
MAO inhibitor; serotonin releasing agent (1) ·
Monoamine releasing agent (5) ·
Monoamine releasing agent; 5-HT2A agonist (1) ·
Monoamine releasing agent; active ingredient in khat (1) ·
Monoamine releasing agent; serotonergic at higher doses (1) ·
Norepinephrine and dopamine releasing agent (1) ·
Norepinephrine/dopamine releasing agent (1) ·
Norepinephrine/dopamine reuptake inhibitor (1) ·
Serotonin releasing agent (2) ·
Serotonin releasing agent; 5-HT2A agonist (3) ·
Serotonin releasing agent; monoamine reuptake inhibitor (1) ·
Serotonin/dopamine/norepinephrine releasing agent; 5-HT2A agonist (1) ·
Serotonin/norepinephrine/dopamine releasing agent (3) ·
'"`UNIQ--vote-000011D5-QINU`"' Minimal systemic absorption and the dual mechanism underlie its first-line role in seasonal allergic conjunctivitis. Comfort drops without preservatives are available for sensitive patients'"`UNIQ--ref-000011D6-QINU`"'. (1) ·
'"`UNIQ--vote-00001284-QINU`"' Systemic oral ketotifen (available outside US) has historical use for asthma adjunct therapy via the same dual mechanism, but oral use produces sedation and weight gain — the topical ophthalmic application largely avoids both'"`UNIQ--ref-00001285-QINU`"'. (1) ·
'"`UNIQ--vote-000013B1-QINU`"' Topical application minimizes systemic antihistaminic burden; the characteristic bitter taste with nasal use (drainage to oropharynx) is the main tolerability issue'"`UNIQ--ref-000013B2-QINU`"'. (1)
uses:
starting dose:
None (25) ·
Intranasal 0.1% or 0.15%: 1-2 sprays/nostril BID; ophthalmic 0.05%: 1 drop in each eye BID (1) ·
Ophthalmic 1 drop in each eye every 8-12 hours (1) ·
Ophthalmic Pataday 0.7%: 1 drop in each eye once daily (24-hour formulation); Patanol 0.1% BID; intranasal Patanase 2 sprays/nostril BID (1)
preparations:
None (25) ·
0.025%, 0.035% ophthalmic solutions (1) ·
0.1% (Patanol), 0.2% (Pataday once-daily original), 0.7% (Pataday 24-hour) ophthalmic solutions; 0.6% nasal spray (1) ·
0.1%, 0.15% intranasal spray; 0.05% ophthalmic solution; combination Dymista (azelastine 0.137 mg + fluticasone 50 mcg/spray) (1)
fda max:
routes:
duration:
halflife:
bioavailability:
pregnancy:
None (25) ·
Generally considered safe (minimal systemic exposure).<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Generally considered safe; minimal systemic exposure.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Limited data; second-line to intranasal corticosteroids or PO loratadine/cetirizine.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1)
Showing below up to 33 results in range #1 to #33.